| Dr Ashkan Bahin-aein, MD | |
|
2375 E Prater Way, Sparks, NV 89434-9641 | |
| (775) 352-5301 | |
| (775) 352-5303 |
| Full Name | Dr Ashkan Bahin-aein |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 18 Years |
| Location | 2375 E Prater Way, Sparks, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508983057 | NPI | - | NPPES |
| 1508983057 | Other | NPI | |
| 12162269 | Other | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 13169 (Nevada) | Primary |
| 207R00000X | Internal Medicine | 13169 (Nevada) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Whiteriver Phs Indian Hospital | Whiteriver, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dhhs Ihs Phoenix Area | 2668649567 | 63 |
News Archive
Novadaq Technologies today announced that it has been granted a patent by the United States Patent and Trademark Office for the SPY(TM) Intra-operative Imaging System (SPY System).
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.
Oral administration of a cocktail of three viruses, all of which specifically kill cholera bacteria, prevents infection and cholera-like symptoms in animal model experiments, report scientists from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts in Nature Communications on Feb. 1.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
› Verified 7 days ago
| Entity Name | Dhhs Ihs Phoenix Area |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427335140 PECOS PAC ID: 2668649567 Enrollment ID: O20120117000781 |
News Archive
Novadaq Technologies today announced that it has been granted a patent by the United States Patent and Trademark Office for the SPY(TM) Intra-operative Imaging System (SPY System).
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.
Oral administration of a cocktail of three viruses, all of which specifically kill cholera bacteria, prevents infection and cholera-like symptoms in animal model experiments, report scientists from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts in Nature Communications on Feb. 1.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ashkan Bahin-aein, MD Po Box 740433, Los Angeles, CA 90074-0433 Ph: (775) 352-5301 | Dr Ashkan Bahin-aein, MD 2375 E Prater Way, Sparks, NV 89434-9641 Ph: (775) 352-5301 |
News Archive
Novadaq Technologies today announced that it has been granted a patent by the United States Patent and Trademark Office for the SPY(TM) Intra-operative Imaging System (SPY System).
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.
Oral administration of a cocktail of three viruses, all of which specifically kill cholera bacteria, prevents infection and cholera-like symptoms in animal model experiments, report scientists from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts in Nature Communications on Feb. 1.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
› Verified 7 days ago
Satwant Mangat, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2375 E Prater Way, Sparks, NV 89434 Phone: 775-331-7000 | |
Dr. Jordan Wu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2375 E Prater Way, Sparks, NV 89434 Phone: 775-331-7000 |